China TCM (570.HK) Update - Behind The Share Price Plunge and Prospects for Privatization Progress

Xinyao has highlighted this Insight as a Top Pick
850 Views03 Jul 2024 08:55
Recent high-level changes in CNPGC are slowing down China TCM's privatization progress. It's expected to hear new progress under new leadership.China TCM’s has strong fundamentals to support valuation
What is covered in the Full Insight:
  • Introduction
  • High-Level Personnel Changes at CNPGC
  • Privatization Progress and Regulatory Requirements
  • China TCM’s Strong Fundamentals
  • Investment Conclusion and Share Price Outlook
Boomeranged on Tue, 16 Jul 2024 09:02
A key message from the latest announcement is "Privatization is still on track.The deal isn't dead",which is in line with our analysis.Given the changes at the top of CNPGC and cumbersome approval process within SOE, current progress is slow but manageable.Since approval is in "advanced stage," August update is eye-catching. So far, we don't have evidence to prove that the Offeror has changed mind
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x